Charles Schwab Investment Management Inc Clene Inc. Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.95 - $1.62 $24,407 - $41,621	25,692 New	25,692 $29,000
Q2 2022 Aug 15, 2022	SELL	$2.1 - $4.12 $141,892 - $278,380	-67,568 Reduced 41.12%	96,741 $244,000
Q1 2022 May 13, 2022	BUY	$2.42 - $4.42 $75,569 - $138,023	31,227 Added 23.46%	164,309 $648,000
Q4 2021 Feb 11, 2022	SELL	$3.95 - $7.53 $38,484 - $73,364	-9,743 Reduced 6.82%	133,082 $546,000
Q3 2021 Nov 16, 2021	SELL	$6.83 - $13.58 $31,192 - $62,019	-4,567 Reduced 3.1%	142,825 $976,000
Q2 2021 Aug 16, 2021	BUY	$6.98 - $13.33 $356,398 - $680,629	51,060 Added 53.0%	147,392 $1.66 Million
Q1 2021 May 17, 2021	BUY	$6.39 - $16.3 $615,561 - $1.57 Million	96,332 New	96,332 $1.23 Million

230K

25K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $273M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.